Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …

Background Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was
approved on the basis of a significant improvement in disease-free survival in the KEYNOTE …

Background Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in
clear-cell renal-cell carcinoma in early-phase studies. Methods In a phase 3, multicenter …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

Background The efficacy and safety of treatment with cabozantinib in combination with
nivolumab and ipilimumab in patients with previously untreated advanced renal-cell …

The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Standard first-line chemotherapy results in disease progression and death within one year in
most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro …

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …